Victoria Johnson

Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.

Combining interventions yielded no significant differences in outcomes, pain, or quality-of-life.

Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.

The pain reduction effects did not last long beyond the scope of the trial, underscoring the importance of continuing such exercises.

SGLT-2 inhibitors had more protective effects than GLP-1 receptor agonists or DPP-4 inhibitors in this population.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.

The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.

SF-36v2 scores also improved by 12 points with semaglutide compared with 6.5 points with placebo.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.

Investigators analyzed antibody response after 2 SARS-CoV-2 vaccinations.

The treatment did seem to blunt the glycemic response and influence some inflammatory cytokines.

The ER fluticasone propionate intra-articular injection significantly reduced pain compared with control for up to 14 weeks.

The study also identified a tendency for more prevalent human herpesvirus 6B in people with FM than in those without.

Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.

Two pivotal phase 3 studies previously met their endpoints of significantly reducting daily pain compared with placebo.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

Over 70% of participants with MSK pain after COVID-19 fulfilled ACR fibromyalgia criteria in new research.

Calabrese discussed considerations for patients with rheumatic disease diagnosed with COVID-19 and the virus’s role in promoting inflammation.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.

Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

Mease discussed the importance of comparator studies in a growing treatment landscape for PsA.

The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.

Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.

The all-optical PAT scanner reduces acquisition time from minutes to seconds and can visualize microvasculature changes to depths approaching 15 mm.